Macrophage-derived Tumor Necrosis Factor-α mediates diabetic renal injury

[1]  G. Bruno,et al.  Inflammation in diabetic nephropathy: moving toward clinical biomarkers and targets for treatment , 2015, Endocrine.

[2]  T. Fujimura,et al.  Role of the TNF pathway in the progression of diabetic nephropathy in KK-A(y) mice. , 2014, American journal of physiology. Renal physiology.

[3]  S. Chadban,et al.  TLR4 Activation Promotes Podocyte Injury and Interstitial Fibrosis in Diabetic Nephropathy , 2014, PloS one.

[4]  W. Liao,et al.  Biologic therapy in erythrodermic and pustular psoriasis. , 2014, Journal of drugs in dermatology : JDD.

[5]  T. Cooper,et al.  Macrophages directly mediate diabetic renal injury. , 2013, American journal of physiology. Renal physiology.

[6]  Beilei Lei,et al.  Tumor necrosis factor alpha antagonism improves neurological recovery in murine intracerebral hemorrhage , 2013, Journal of Neuroinflammation.

[7]  S. Morris,et al.  Arginase inhibition mediates renal tissue protection in diabetic nephropathy by a nitric oxide synthase 3-dependent mechanism , 2013, Kidney international.

[8]  K. Lai,et al.  The TLR4 antagonist CRX-526 protects against advanced diabetic nephropathy. , 2013, Kidney international.

[9]  P. V. Schouwenburg,et al.  Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis , 2013, Nature Reviews Rheumatology.

[10]  H. Freeman,et al.  Use of the tumor necrosis factor-blockers for Crohn's disease. , 2012, World journal of gastroenterology.

[11]  E. Abdel-Rahman,et al.  Therapeutic Modalities in Diabetic Nephropathy: Standard and Emerging Approaches , 2012, Journal of General Internal Medicine.

[12]  T. Mayadas,et al.  Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. , 2012, Journal of the American Society of Nephrology : JASN.

[13]  T. Mayadas,et al.  Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. , 2012, Journal of the American Society of Nephrology : JASN.

[14]  M. Okusa,et al.  Monocyte/macrophage chemokine receptor CCR2 mediates diabetic renal injury. , 2011, American journal of physiology. Renal physiology.

[15]  S. Morris,et al.  Arginase-2 Mediates Diabetic Renal Injury , 2011, Diabetes.

[16]  P. Tobias,et al.  Knockout of toll-like receptor-4 attenuates the pro-inflammatory state of diabetes. , 2011, Cytokine.

[17]  J. Navarro-González,et al.  Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy , 2011, Nature Reviews Nephrology.

[18]  T. Greene,et al.  Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design , 2011, BMC nephrology.

[19]  D. Williamson,et al.  Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence , 2010, Population health metrics.

[20]  M. Graham,et al.  Evaluation of an Anti-Tumor Necrosis Factor Therapeutic in a Mouse Model of Niemann-Pick C Liver Disease , 2010, PloS one.

[21]  C. Alpers,et al.  Mouse models of diabetic nephropathy. , 2005, Journal of the American Society of Nephrology : JASN.

[22]  George Kollias,et al.  The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. , 2009, The Journal of clinical investigation.

[23]  G. Camussi,et al.  Effect of the Monocyte Chemoattractant Protein-1/CC Chemokine Receptor 2 System on Nephrin Expression in Streptozotocin-Treated Mice and Human Cultured Podocytes , 2009, Diabetes.

[24]  S. Leroy,et al.  Successful Anti‐TNFα Treatment in a Child with Posttransplant Recurrent Focal Segmental Glomerulosclerosis , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[25]  T. Yoo,et al.  MCP-1/CCR2 system is involved in high glucose-induced fibronectin and type IV collagen expression in cultured mesangial cells. , 2008, American journal of physiology. Renal physiology.

[26]  GH Tesch.  ROLE OF MACROPHAGES IN COMPLICATIONS OF TYPE 2 DIABETES , 2007, Clinical and experimental pharmacology & physiology.

[27]  P. Goldstraw,et al.  Differential Regulation of Cytokine Release and Leukocyte Migration by Lipopolysaccharide-Stimulated Primary Human Lung Alveolar Type II Epithelial Cells and Macrophages1 , 2007, The Journal of Immunology.

[28]  K. Nomura,et al.  Correlations of tissue macrophages and cytoskeletal protein expression with renal fibrosis in patients with diabetes mellitus , 2006, Clinical and Experimental Nephrology.

[29]  N. Sheerin,et al.  Toll‐like receptors TLR2 and TLR4 initiate the innate immune response of the renal tubular epithelium to bacterial products , 2006, Clinical and experimental immunology.

[30]  R. Atkins,et al.  Macrophage accumulation in human progressive diabetic nephropathy , 2006, Nephrology.

[31]  Liping Huang,et al.  Adenosine A2A receptor activation attenuates inflammation and injury in diabetic nephropathy. , 2006, American journal of physiology. Renal physiology.

[32]  R. Atkins,et al.  Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice. , 2005, Journal of the American Society of Nephrology : JASN.

[33]  J. Vacher,et al.  Targeted expression of Cre recombinase in macrophages and osteoclasts in transgenic mice , 2005, Genesis.

[34]  S. Kelsen,et al.  Regulation of interleukin-1β and interleukin-1β inhibitor release by human airway epithelial cells , 2004, European Respiratory Journal.

[35]  D. Raveh,et al.  Tumor necrosis factor-α blocking agent as a treatment for nephrotic syndrome , 2004, Pediatric Nephrology.

[36]  K. Wu,et al.  Dual Regulation of Tumor Necrosis Factor-α-Induced CCL2/Monocyte Chemoattractant Protein-1 Expression in Vascular Smooth Muscle Cells by Nuclear Factor-κB and Activator Protein-1: Modulation by Type III Phosphodiesterase Inhibition , 2004, Journal of Pharmacology and Experimental Therapeutics.

[37]  F. Gesek,et al.  Pentoxifylline Ameliorates Renal Tumor Necrosis Factor Expression, Sodium Retention, and Renal Hypertrophy in Diabetic Rats , 2004, American Journal of Nephrology.

[38]  F. Gesek,et al.  Tumor necrosis factor induces sodium retention in diabetic rats through sequential effects on distal tubule cells. , 2004, Kidney international.

[39]  R. Schnellmann,et al.  Role of an Endoplasmic Reticulum Ca2+-Independent Phospholipase A2 in Cisplatin-Induced Renal Cell Apoptosis , 2004, Journal of Pharmacology and Experimental Therapeutics.

[40]  G. Ramesh,et al.  TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure. , 2003, American journal of physiology. Renal physiology.

[41]  H. Siragy,et al.  Urinary and renal interstitial concentrations of TNF-alpha increase prior to the rise in albuminuria in diabetic rats. , 2003, Kidney international.

[42]  F. Thaiss,et al.  Expression of the chemokines MCP-1/CCL2 and RANTES/CCL5 is differentially regulated by infiltrating inflammatory cells. , 2002, Kidney international.

[43]  G. Ramesh,et al.  TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity , 2002 .

[44]  J. Skepper,et al.  Expression of Tumor Necrosis Factor Receptors in Normal Kidney and Rejecting Renal Transplants , 2001, Laboratory Investigation.

[45]  S. Akira,et al.  Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. , 1999, Journal of immunology.

[46]  M. Perretti,et al.  Regulation of macrophage inflammatory protein-1 alpha expression and function by endogenous interleukin-10 in a model of acute inflammation. , 1999, Biochemical and biophysical research communications.

[47]  M. Perretti,et al.  Role of resident peritoneal macrophages and mast cells in chemokine production and neutrophil migration in acute inflammation: evidence for an inhibitory loop involving endogenous IL-10. , 1999, Journal of immunology.

[48]  H. Makino,et al.  Increased expression of selectins in kidneys of patients with diabetic nephropathy , 1998, Diabetologia.

[49]  L. Owen-Schaub,et al.  Human Tumor Necrosis Factor Receptor p75/80 (CD120b) Gene Structure and Promoter Characterization* , 1996, The Journal of Biological Chemistry.

[50]  K. Yoshinaga,et al.  The role of macrophages in diabetic glomerulosclerosis. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[51]  Y. Tomino,et al.  mRNA Expression of Growth Factors in Glomeruli From Diabetic Rats , 1993, Diabetes.

[52]  M. Kondo,et al.  Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. , 1991, Kidney international.

[53]  P. Tipping,et al.  Tumor necrosis factor production by glomerular macrophages in anti-glomerular basement membrane glomerulonephritis in rabbits. , 1991, Laboratory investigation; a journal of technical methods and pathology.

[54]  Z. Hruby,et al.  Spontaneous release of tumor necrosis factor alpha by isolated renal glomeruli and cultured glomerular mesangial cells. , 1991, Clinical immunology and immunopathology.

[55]  A Bohle,et al.  The pathogenesis of chronic renal failure in diabetic nephropathy. Investigation of 488 cases of diabetic glomerulosclerosis. , 1991, Pathology, research and practice.

[56]  Leonard,et al.  Cytokine-activated human endothelial cells synthesize and secrete a monocyte chemoattractant, MCP-1/JE. , 1990, The American journal of pathology.

[57]  J. Oudinet,et al.  Production of tumor necrosis factor by rat mesangial cells in response to bacterial lipopolysaccharide. , 1989, Kidney international.

[58]  C. Nathan,et al.  Secretory products of macrophages. , 1987, The Journal of clinical investigation.

[59]  J. Navarro-González,et al.  Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial. , 2015, Journal of the American Society of Nephrology : JASN.

[60]  Jagdeep Nanchahal,et al.  Anti-TNF therapy: past, present and future. , 2015, International immunology.

[61]  K. Chan,et al.  Toll-like receptor 4 promotes tubular inflammation in diabetic nephropathy. , 2012, Journal of the American Society of Nephrology : JASN.

[62]  H. Anders,et al.  Cardiovascular , Pulmonary and Renal Pathology Late Onset of Ccl 2 Blockade with the Spiegelmer mNOX-E 36 – 3 PEG Prevents Glomerulosclerosis and Improves Glomerular Filtration Rate in db / db Mice , 2010 .

[63]  R. Atkins,et al.  Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. , 2006, Kidney international.

[64]  H. Parving,et al.  Urinary connective tissue growth factor excretion correlates with clinical markers of renal disease in a large population of type 1 diabetic patients with diabetic nephropathy. , 2006, Diabetes care.

[65]  B. Ryffel,et al.  Distinct and nonredundant in vivo functions of TNF produced by t cells and macrophages/neutrophils: protective and deleterious effects. , 2005, Immunity.

[66]  D. Raveh,et al.  Tumor necrosis factor-alpha blocking agent as a treatment for nephrotic syndrome. , 2004, Pediatric nephrology.

[67]  S. Kelsen,et al.  Regulation of interleukin-1beta and interleukin-1beta inhibitor release by human airway epithelial cells. , 2004, The European respiratory journal.

[68]  F. Gesek,et al.  Urinary tumor necrosis factor contributes to sodium retention and renal hypertrophy during diabetes. , 2003, American journal of physiology. Renal physiology.

[69]  M. Kakei,et al.  Association of monocyte chemoattractant protein-1 with renal tubular damage in diabetic nephropathy. , 2003, Journal of diabetes and its complications.

[70]  E. Lerut,et al.  Benefit of anti-TNF a treatment for nephrotic syndrome in a patient with juvenile inflammatory bowel disease associated spondyloarthropathy complicated with amyloidosis and glomerulonephritis , 2003 .

[71]  G. Ramesh,et al.  TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. , 2002, The Journal of clinical investigation.

[72]  C. Tsai,et al.  Increased excretion of tumor necrosis factor alpha and interleukin 1 beta in urine from patients with IgA nephropathy and Schönlein-Henoch purpura. , 1996, Nephron.